CNS LESION
Clinical trials for CNS LESION explained in plain language.
Never miss a new study
Get alerted when new CNS LESION trials appear
Sign up with your email to follow new studies for CNS LESION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New MRI dye shows promise in japanese patients
Diagnosis CompletedThis completed Phase 3 trial tested gadopiclenol, a new MRI contrast agent, in 240 Japanese adults and children with known or suspected lesions in the brain or body. The study compared a lower dose of gadopiclenol to a standard dose of gadobutrol to see if it could provide equall…
Matched conditions: CNS LESION
Phase: PHASE3 • Sponsor: Guerbet • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
New Gadolinium-Free MRI dye shows promise for brain scans
Diagnosis CompletedThis study tested a new MRI contrast agent called RVP-001, made with manganese instead of gadolinium, in 18 adults with known brain lesions (like tumors or multiple sclerosis). The goal was to see if it is safe and can detect lesions as well as current gadolinium-based dyes. Each…
Matched conditions: CNS LESION
Phase: PHASE2 • Sponsor: Reveal Pharmaceuticals Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 08:06 UTC
-
New contrast dye could sharpen brain scans
Diagnosis CompletedThis Phase 3 trial tested a new contrast agent called gadopiclenol for MRI scans of the brain and spine. The study involved 260 people with known or suspected central nervous system lesions. The goal was to see if gadopiclenol improves the visibility of lesions compared to scans …
Matched conditions: CNS LESION
Phase: PHASE3 • Sponsor: Guerbet • Aim: Diagnosis
Last updated Jun 27, 2026 07:51 UTC